BCV
RNAC icon

Banque Cantonale Vaudoise’s Cartesian Therapeutics RNAC Stock Holding History

Banque Cantonale Vaudoise’s Portfolio RNAC Stock Details RNAC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-2,433
Closed -$305K – 1346
2021
Q2 		$305K Buy
+2,433
New +$290K 0.01% 740

Other funds holding RNAC

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
MWNA
Marshall Wace North America New York $23.5B AUM 46.46% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Banque Cantonale Vaudoise's RNAC Position: Q3 2021 in Review

Banque Cantonale Vaudoise sold out of Cartesian Therapeutics (RNAC) in Q3 2021, closing a stake of 2,433 shares — an estimated $305K sold.

Banque Cantonale Vaudoise first reported a position in RNAC in Q2 2021 and held it in 1 quarter. The position peaked at $305K in Q2 2021. 103 funds tracked by Wall St. Rank hold RNAC as of Q3 2021.

  • Banque Cantonale Vaudoise reported no remaining Cartesian Therapeutics position as of Q3 2021 after selling out during the quarter.
  • Banque Cantonale Vaudoise sold 2,433 Cartesian Therapeutics shares in Q3 2021, an estimated $305K.
  • Banque Cantonale Vaudoise first reported a position in Cartesian Therapeutics in Q2 2021 and held it in 1 quarter.
  • Banque Cantonale Vaudoise's Cartesian Therapeutics position peaked at $305K in Q2 2021.
  • 103 funds tracked by Wall St. Rank held Cartesian Therapeutics as of Q3 2021.

Based on Banque Cantonale Vaudoise's 13F filing for Q3 2021, filed 29 Oct 2021.